Heparin and its anti-inflammatory action in the gut;Heparyna i jej działanie przeciwzapalne w układzie pokarmowym

Gastroenterologia Polska

Volumn 17, Issue 3, 2010, Pages 227-233

  Warzecha, Zygmunt ^a   Dembiński, Marcin ^a   Ceranowicz, Piotr ^a   Dembiński, Artur ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Acute pancreatitis; Colitis; Heparin; Liver

Indexed keywords

FIBRIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN;

ACUTE PANCREATITIS; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; COLITIS; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; GASTROINTESTINAL TRACT; HUMAN; MONOCYTE; NONHUMAN; REVIEW;

EID: 77956413760     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Motlekar N.A., Youan B.B.C.: The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins. J. Control. Release, 2006,113, 91-101.
2. Bowman W.C., Rand M.J.: The blood: drugs affecting coagulation, fibrinolysis, haematopoiesis and functioning of blood cells. [w:] Textbook of pharmacology. (red.) W.C. Bowman, M.J. Rand. Blackwell Scientific Publication, Oxford, 1980, 21.15-21.16.
3. Partyka Ł., Dembińska-Kieć A., Janikowski M., Obtułowicz A.: Diagnostyka układu krzepniȩcia oraz monitorowanie leczenia przeciwkrzepliwego i fibrynolitycznego. [w:] Diagnostyka laboratoryjna z elementami biochemii klinicznej. (red.) A. Dembińska- Kieć, J.W. Nadskalski. Volumed, Wrocław, 1998, 308-317.
4. Esmon C.T.: The interaction between inflammation and coagulation. Br. J. Haematol., 2005, 131, 417-430.
5. Esmon C.T.: Crosstalk between inflammation and thrombosis. Maturitas, 2008, 61, 122-131.
6. Maugeri N., Brambilla M., Camera M., Carbone A., Tremoli E., Donati M.B., de Gaetano G., Cerletti C.: Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J. Thromb. Haemost., 2006, 4, 1323-1330.
7. Opal S.M.: Therapeutic rationale for antithrombin III in sepsis. Crit. Care Med., 2000, 28, supl. 9, S34-S37.
8. Heyderman R.S., Klein N.J., Shennan G.I., Levin M.: Reduction of the anticoagulant activity of glycosaminoglycans on the surface of the vascular endothelium by endotoxin and neutrophils: evaluation by an amidolytic assay. Thromb. Res., 1992, 67, 677-685.
9. Conway E.M., Rosenberg R.D.: Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol. Cell. Biol., 1988, 8, 5588-5592.
10. Faust S.N., Levin M., Harrison O.B., Goldin R.D., Lockhart M.S., Kondaveeti S., Laszik Z., Esmon C.T., Heyderman R.S.: Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med., 2001, 345, 408-416.
11. Camerer E., Rottingen J.A., Gjernes E., Larsen K., Skartlien A.H., Iversen J.G., Prydz H.: Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J. Biol. Chem., 1999, 274, 32225-32233.
12. Camerer E., Kataoka H., Kahn M., Lease K., Coughlin S.R.: Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J. Biol. Chem., 2002, 277, 16081-16087.
13. Cunningham M.A., Romas P., Hutchinson P., Holdsworth S.R., Tipping PG.: Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood, 1999, 94, 3413-3420.
14. Loike J.D., el Khoury J., Cao L., Richards C.P., Rascoff H., Mandeville J.T., Maxfield F.R., Silverstein S.C.: Fibrin regulates neutrophil migration in response to interleukin 8, leukotriene B4, tumor necrosis factor, and formyl-methionyl-leucyl-phenylalanine. J. Exp. Med., 1995, 181, 1763-1772.
15. Skogen W.F., Senior R.M., Griffin G.L., Wilner G.D.: Fibrinogen-derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood, 1988, 71, 1475-1479.
16. Qi J., Goralnick S., Kreutzer D.L.: Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. Blood, 1997, 90, 3595-3602.
17. Bar-Shavit R., Kahn A., Fenton J.W. 2nd, Wilner G.D.: Chemotactic response of monocytes to thrombin. J. Cell. Biol., 1983, 96, 282-285.
18. Jin Y, Nonoyama S, Morio T, Imai K, Ochs HD, Mizutani S.: Characterization of soluble CD40 ligand released from human activated platelets. J. Med. Dent. Sci., 2001, 48, 23-27.
19. Enomoto Y., Adachi S., Matsushima-Nishiwaki R., Doi T., Niwa M., Akamatsu S., Tokuda H., Ogura S., Yoshimura S., Iwama T., Kozawa O.: Thromboxane A(2) promotes soluble CD40 ligand release from human platelets. Atherosclerosis, 2010, 209, 415-421.
20. Croce K., Libby P.: Intertwining of thrombosis and inflammation in atherosclerosis. Curr. Opin. Hematol., 2007, 14, 55-61.
21. Young E.: The anti-inflammatory effects of heparin and related compounds. Thromb. Res., 2008, 122, 743-752.
22. Tyrrell D.J., Horne A.P., Holme K.R., Preus J.M., Page C.P.: Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv. Pharmacol., 1999, 46, 151-208.
23. Ceranowicz P., Dembinski A., Warzecha Z., Dembinski M., Cieszkowski J., Rembiasz K., Konturek S.J., Kusnierz-Cabala B., Tomaszewska R., Pawlik W.W.: Protective and therapeutic effect of heparin in acute pancreatitis. J. Physiol. Pharmacol., 2008, 59, supl. 4, 103-125.
24. Axelsson J., Ferreira M., Adolfsson L., McCrea K., Ward R., Larm O., Cytokines in blood from septic patients interact with surface-immobilized heparin. ASAIO J., 2010, 56, 48-51.
25. Lever R., Smailbegovic A., Page CP.: Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity. Eur. J. Pharmacol., 2010, 630, 137-144.
26. Brown R.A., Lever R., Jones N.A., Page C.P.: Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro. Br. J. Pharmacol., 2003,139, 845-853. (Pubitemid 36819612)
27. Hornebeck W., Lafuma C., Robert L., Móczár M., Móczár E.: Heparin and its derivatives modulate serine proteinases (SERPS) serine proteinase inhibitors (SERPINS) balance. Physiopathological relevance. Pathol. Res. Pract., 1994, 190, 895-902.
28. Sissi C., Lucatello L., Naggi A., Torri G., Palumbo M.: Interactions of low-molecular-weight semi-synthetic sulfated heparins with human leukocyte elastase and human cathepsin G. Biochem. Pharmacol. 2006, 71, 287-293.
29. Ewangelista V, Piccardoni P, Maugeri N, De Gaetano G, Cerletti C. Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G. Eur. J. Pharmacol., 1992, 216, 401-405.
30. Nelson R.M., Cecconi O., Roberts W.G., Aruffo A., Linhardt R.J., Bevilacqua M.P.: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood, 1993, 82, 3253-3258.
31. Diamond M.S., Garcia-Aguilar J., Bickford J.K., Corbi A.L., Springer T.A.: The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J. Cell. Biol., 1993, 120, 1031-1043.
32. Peter K., Schwarz M., Conradt C., Nordt T., Moser M., Kübler W., Bode C.: Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Circulation, 1999, 100, 1533-1539.
33. Lee J.H., Kim C.H., Seo G.H., Lee J., Kim J.H., Kim D.G., Ahn Y.S.: Heparin attenuates the expression of TNF alpha-induced cerebral endothelial cell adhesion molecule. Korean J. Physiol. Pharmacol., 2008, 12, 231-236.
34. Wulczyn F.G., Krappmann D., Scheidereit C.: The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. J. Mol. Med., 1996, 74, 749-769.
35. Karin M., Ben-Neriah Y.: Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol., 2000, 18, 621-663.
36. Thourani V.H., Brar S.S., Kennedy T.P., Thornton L.R., Watts J.A., Ronson R.S., Zhao Z.Q., Sturrock A.L., Hoidal J.R., Vinten-Johansen J.: Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2000, 278, H2084-H2093.
37. Hochart H., Jenkins P.V., Smith O.P., White B.: Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-κB in LPS-stimulated human monocytes. Br. J. Haematol., 2006, 133, 62-67.
38. Hecht I., Hershkoviz R., Shivtiel S., Lapidot T., Cohen I.R., Lider O., Cahalon L.: Heparin-disaccharide affects T cells: inhibition of NF-kappaB activation, cell migration, and modulation of intracellular signaling. J. Leukoc. Biol., 2004, 75, 1139-1146.
39. Manduteanu I., Voinea M., Antohe F., Dragomir E., Capraru M., Radulescu L., Simionescu M.: Effect of enoxaparin on high glucose-induced activation of endothelial cells. Eur. J. Pharmacol., 2003, 477, 269-276.
40. Bowler S.D., Smith S.M., Lavercombe P.S.: Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am. Rev. Respir. Dis., 1993, 147, 160-163.
41. Saliba M.J. Jr.: Heparin in the treatment of burns: a review. Burns, 2001, 27, 349-358.
42. Aldea G.S., Soltow L.O., Chandler W.L., Triggs C.M., Vocelka C.R., Crockett G.I., Shin Y.T., Curtis W.E., Verrier E.D.: Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J. Thorac. Cardiovasc. Surg., 2002, 123, 742-755.
43. Bernstein C.N., Blanchard J.F., Houston D.S., Wajda A.: The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost., 2001, 85, 430-434.
44. Koutroubakis I.E., Theodoropoulou A., Xidakis C., Sfiridaki A., Notas G., Kolios G., Kouroumalis E.A.: Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol., 2004, 16, 1147-1152.
45. Dhillon A.P., Anthony A., Sim R., Wakefield A.J., Sankey E.A., Hudson M., Allison M.C., Pounder R.E.: Mucosal capillary thrombi in rectal biopsies. Histopathology, 1992, 21, 127-133.
46. Dwarakanath A.D., Yu L.G., Brookes C., Pryce D., Rhodes J.M.: 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut, 1995,37, 585-588.
47. Folwaczny C., Wiebecke B., Loeschke K.: Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am. J. Gastroenterol., 1999, 94: 1551-1555.
48. Gaffney P.R., Doyle C.T., Gaffney A., Hogan J., Hayes D.P., Annis P.: Paradoxical response to heparin in 10 patients with ulcerative colitis. Am. J. Gastroenterol., 1995, 90, 220-223.
49. Törkvist L., Thorlacius H., Sjöqvist U., Bohman L., Lapidus A., Flood L., Agren B., Raud J., Löfberg R.: Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment. Pharmacol. Ther., 1999, 13, 1323-1328.
50. Vrij A.A., Jansen J.M., Schoon E.J., de Bruïne A., Hemker H.C., Stockbrügger R.W.: Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand. J. Gastroenterol. Suppl., 2001, 234, 41-47.
51. Ang Y.S., Mahmud N., White B., Byrne M., Kelly A., Lawler M., McDonald G.S., Smith O.P., Keeling P.W.: Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment. Pharmacol. Ther., 2000, 14, 1015-1022.
52. Panés J., Esteve M., Cabré E, Hinojosa J., Andreu M., Sans M., Fernandez-Bañares F., Feu F., Gassull M.A., Piqué J.M.: Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology, 2000, 119, 903-908.
53. Bloom S., Kiilerich S., Lassen M.R., Forbes A, Leiper K., Langholz E., Irvine E.J., O'Morain C., Lowson D., Orm S.: Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment. Pharmacol. Ther., 2004, 19, 871-878.
54. de Bièvre M.A., Vrij A.A., Schoon E.J., Dijkstra G., de Jong A.E., Oberndorff-Klein Woolthuis A.H., Hemker H.C., Stockbrügger R.W.: Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. Inflamm. Bowel. Dis., 2007, 13, 753-758.
55. Zezos P., Papaioannou G., Nikolaidis N., Patsiaoura K., Papageorgiou A., Vassiliadis T., Giouleme O., Evgenidis N.: Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. Aliment. Pharmacol. Ther., 2006, 23, 1443-1453.
56. Shen J., Ran Z.H., Tong J.L., Xiao S.D.: Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment. Pharmacol. Ther., 2007, 26, 653-663.
57. Chande N., McDonald J.W., Macdonald J.K.: Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2008, 2, CD006774.
58. Ceranowicz P., Dembiński M., Warzecha Z., Cieszkowski J., Kuśnierz-Cabala B., Tomaszewska R., Dembiński A.: Leczniczy efekt heparyny w przebiegu ostrego zapalenia trzustki wywołanego ceruleina̧. Przegla̧d Gastroenterol., 2009, 4, 199-205.
59. Lasson A., Ohlsson K.: Consumptive coagulopathy, fibrinolysis and protease-antiprotease interactions during acute human pancreatitis. Thromb. Res., 1986, 41, 167-183.
60. Salomone T., Tosi P., Palareti G., Tomassetti P., Migliori M., Guariento A., Saieva C., Raiti C., Romboli M., Gullo L.: Coagulative disorders in human acute pancreatitis: role for the D-dimer. Pancreas, 2003, 26, 111-116.
61. Radenković D., Bajec D., Karamarkovic A., Stefanovic B., Milic N., Ignjatović S., Gregoric P., Milicevic M.: Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Pancreas, 2004, 29, 152-156.
62. Maeda K., Hirota M., Ichihara A., Ohmuraya M., Hashimoto D., Sugita H., Takamori H., Kanemitsu K., Baba H.: Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. Pancreas, 2006, 32, 87-92.
63. Agarwal N., Pitchumoni C.S.: Acute pancreatitis: a multisystem disease. Gastroenterologist., 1993, 1, 115-128.
64. Saif M.W.: DIC secondary to acute pancreatitis. Clin. Lab. Haematol., 2005, 27, 278-282.
65. Dobosz M., Wajda Z., Hac S., Myśliwska J., Mionskowska L., Bryl E., Roszkiewicz A., Myśliwski A.: Heparin and nitric oxide treatment in experimental acute pancreatitis in rats. Forum (Genova), 1998, 8, 303-310.
66. Gabryelewicz A., Niewiarowski S., Prokopowicz J., Chlebowski J.: Heparin and protease inhibitors in the prevention of experimental acute pancreatic necrosis in dogs. Digestion, 1969, 2, 7-16.
67. Qiu F., Lu X.S., Huang Y.K.: Effect of low molecular weight heparin on pancreatic microcirculation in severe acute pancreatitis in a rodent model. Chin. Med. J., 2007, 120, 2260-2263.
68. Rabenstein T., Roggenbuck S., Framke B., Martus P., Fischer B., Nusko G., Muehldorfer S., Hochberger J., Ell C., Hahn E.G., Schneider H.T.: Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest. Endosc., 2002, 55, 476-483.
69. Barkay O., Niv E., Santo E., Bruck R., Hallak A., Konikoff F.M.: Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial. Surg. Endosc., 2008, 22, 1971-1976.
70. Rabenstein T., Fischer B., Wiessner V., Schmidt H., Radespiel-Tröger M., Hochberger J., Mühldorfer S., Nusko G., Messmann H., Schölmerich J., Schulz H.J., Schönekäs H., Hahn E.G., Schneider H.T.: Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest. Endosc., 2004, 59, 606-613.
71. Stewart J.E., Schotz M.C.: Release of lipoprotein lipase activity from isolated fat cells. II. Effect of heparin. J. Biol. Chem., 1974, 249, 904-907.
72. Alagözlü H., Cindoruk M., Karakan T., Unal S.: Heparin and insulin in the treatment of hypertriglyceridemia-induced severe acute pancreatitis. Dig. Dis. Sci., 2006, 51, 931-933.
73. Kyriakidis A.V., Raitsiou B., Sakagianni A., Harisopoulou V., Pyrgioti M., Panagopoulou A., Vasilakis N., Lambropoulos S.: Management of acute severe hyperlipidemic pancreatitis. Digestion, 2006, 73, 259-264.
74. Jain P., Rai R.R., Udawat H., Nijhawan S., Mathur A.: Insulin and heparin in treatment of hypertriglyceridemia-induced pancreatitis. World J. Gastroenterol., 2007, 13, 2642-2643.
75. Seta T., Noguchi Y., Shimada T., Shikata S., Fukui T.: Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur. J. Gastroenterol. Hepatol., 2004, 16, 1287-1293.
76. Ishikawa T., Imai M., Kamimura H., Ushiki T., Tsuchiya A., Togashi T., Watanabe K., Seki K., Ohta H., Yoshida T., Kamimura T.: Therapeutic efficacy of continuous arterial infusion of the protease inhibitor and the antibiotics and via celiac and superior mesenteric artery for severe acute pancreatitis - pilot study. Hepatogastroenterology, 2009, 56, 524-528.
77. Conrad H.E.: Heparin-binding proteins. Academic Press, New York, London, 1998.
78. Finotti P., Manente S.: Heparin-induced structural and functional alterations of bovine trypsin. Biochim. Biophys. Acta, 1994, 1207, 80-87.
79. Nobar S.M., Guy-Crotte O., Rabaud M., Bieth J.G.: Inhibition of human pancreatic proteinases by human plasma alpha2-antiplasmin and antithrombin. Biol. Chem., 2004, 385, 423-427.
80. Struss D., Storck J., Zimmermann R.E.: The inhibition of thrombin and chymotrypsin by heparin-cofactor II. Trombin. Res., 1992, 68, 45-56.
81. Wolosowicz N., Prokopowicz J., Gabryelewicz A.: The inhibitory effect of heparin on trypsinogen activation with enterokinase. Acta Hepatogastroenterol. (Stuttg.), 1977, 24, 367-371.
82. Gabryelewicz A., Kosidlo S., Prokopowicz J., Podkowicz K.: Does heparin modify protease-antiprotease balance in acute experimental pancreatitis in rats. Hepatogastroenterology, 1986, 33, 79-82
83. Matsumoto T., Yamaguchi M., Kikuchi H., Nakano H., Midorikawa T., Kumada K., Takeda M.: Heparin reduces serum levels of endothelin-1 and hepatic ischemia reperfusion injury in rabbits. Surg. Today, 2000, 30, 523-525.
84. Taha M.O., Gonçalves P.F., Vidigal R.O., Sacchi G.P., Pinheiro F.G., Brandão L.S., Feguri S., Moraes-Filho A.M., Ghadie M.M., Magalhães K.G., Simões M.J., Tersariol I.L., Monteiro H.P., Oliveira I. Jr, Jurkiewicz A., Caricati-Neto A.: Protective effects of heparin on hepatic ischemia and reperfusion lesions in rabbits. Transplant. Proc., 2009, 41, 812-815.
85. Harada N., Okajima K., Uchiba M.: Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion- induced liver injury in rats. Crit. Care Med., 2006, 34, 1883-1891.
86. Bihl F., Janssens F., Boehlen F., Rubbia-Brandt L., Hadengue A., Spahr L.: Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterol., 2010, 10, 6.
87. Yagmurdur M.C., Turk E., Moray G., Can F., Demirbilek M., Haberal N., Karabay G., Karakayali H., Haberal M.: Effects of heparin on bacterial translocation and gut epithelial apoptosis after burn injury in the rat: dose-dependent inhibition of the complement cascade. Burns, 2005, 31, 603-609.
88. Kanabar V., Hirst S.J., O'Connor B.J., Page C.P.: Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle. Br. J. Pharmacol., 2005, 146, 370-377.
89. Ueda K., Inoue S., Zhang Y., Kutsuna T., Inoue S., Noto K., Arai N., Noguchi M.: Heparin induces apoptosis through suppression of AKt in oral squamous cell carcinoma cells. Anticancer Res., 2009, 29, 1079-1088.
90. Mrabat H., Garg H.G., Hales C.A.: Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment. J. Cell. Physiol., 2009, 221, 603-608.
91. Burgess W.H., Maciag T.: The heparin-binding (fibroblast) growth factor family of proteins. Annu. Rev. Biochem., 1989, 58, 575-606.
92. Ashikari-Hada S., Habuchi H., Kariya Y., Itoh N., Reddi A.H., Kimata K.: Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J. Biol. Chem., 2004, 279, 12346-12354.
93. Gitay-Goren H., Soker S., Vlodavski I., Neufeld G.: The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 1992, 267, 6093-6098.
94. Higashiyama S., Abraham J.A., Miller J., Fiddes J.C., Klagsbrun M.: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science, 1991, 251, 936-939.
95. Thompson S.A., Higashiyama S., Wood K., Pollitt N.S., Damm D., McEnroe G., Garrick B., Ashton N., Lau K., Hancock N., Klagsbrun M., Abraham J.A.: Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. J. Biol. Chem., 1994, 269, 2541-2549.
96. Muramatsu T., Muramatsu H.: Glycosaminoglycan-binding cytokines as tumor markers. Proteomics, 2008, 8, 3350-3359.
97. Rapraeger A.C., Krufka A., Olwin B.B.: Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science, 1991, 252, 1705-1708.
98. Ornitz D.M., Leder P.: Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J. Biol. Chem., 1992, 267, 16305-16311.
99. Kan M., Wang F., Xu J., Crabb J.W., Hou J., McKeehan W.L.: An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science, 1993, 259, 1918-1921.
100. Saksela O., Moscatelli D., Sommer A., Rifkin D.B.: Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J. Cell. Biol., 1988, 107, 743-751.
101. Mätzsch T., Bergqvist D., Blomquist P., Jiborn H.: Influence of standard heparin or low molecular weight heparin on healing of abdominal wounds and colonic anastomoses in rats. Acta Chir. Scand., 1987, 153, 593-598.
102. Gunerhan Y., Koksal N., Gul O., Uzun M.A., Guneş P., Adaleti R.: Effects of unfractionated heparin and low-molecular-weight heparin on colonic anastomoses in the presence of experimental peritonitis. Eur. Surg. Res., 2006, 38, 353-357. (Pubitemid 44154685)
103. Eikelboom J.: Nonbleeding complications of unfractionated and low-molecular weight heparins. Clin. Adv. Hematol. Oncol., 2007, 5, 871-873.